Health and FitnessHealth and Fitness
Mon, February 11, 2013
[ Mon, Feb 11th 2013 ] - Market Wire
ASX Trading Suspension Update

Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates


Published on 2013-02-11 01:01:37 - Market Wire
  Print publication without navigation


Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates -- NEW YORK, February 7, 2013 /PRNewswire/ --

NEW YORK, February 7, 2013 /PRNewswire/ --

Zynga reported fourth-quarter earnings and sales late Tuesday, revealing that the Company earned 1 cent per share, or $6.9 million, on sales of $311 million last quarter. Analysts polled by Thomson Reuters expected a loss of 3 cents per share and $212 million in revenue. The Company's tally of daily active users rose to 56 million in the fourth quarter of 2012 meaning 2 million new daily active users were added in the last year.

Whether bull or bear The Stock Freak has got you covered! Sign up to receive our free newsletters and stay up to date with stocks on the run. [ http://www.TheStockFreak.com ]   

Elan Corporation, plc (NYSE: [ ELN ]) - ELN shares closed down 10.23% yesterday at $9.39. The stock was one of the biggest losers on the NYSE on Wednesday even though the Company released strong fourth quarter and full-year 2012 financial results yesterday. Full Year 2012 guidance was met; Pro-forma Revenues up 13%; Adjusted EBITDA was up 31%. Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha-4 integrin inhibitor primarily for the treatment of MS.  Biogen Idec Inc. has agreed to buy partner Elan Corp's stake in the Tysabri multiple sclerosis medicine for $3.25 billion in cash plus future royalties. The number of patients taking Tysabri grew by 12% in 2012. At 63,059,803 shares traded yesterday, volume was roughly thirty times higher than average.

BlackBerry (Nasdaq: [ BBRY ]) - shares of BlackBerry closed in the green for the 5th trading day in a row yesterday. The stock modestly closed up 0.19% on Wednesday on volume almost double the stock's average. Trading volume yesterday was 100,212,704 shares. BlackBerry has been one of the most active stocks on the Nasdaq recently. The Company launched two new phones last week, the Z10 and the Q10, both running a new operating system called BB10. BlackBerry said on Wednesday that the Canadian and U.K. launches of the Z10 have been the best of any of its handsets debuts in those regions ever. The Z10 will not be in stores in the United States until an unspecified point in March.

The Walt Disney Company (NYSE: [ DIS ]) - shares of DIS hit a new 52-week high of $55.50 on Wednesday after the Company released positive first-quarter earnings results. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.02. The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $11.21 billion. The Company's revenue was up 5.2% compared to the same quarter last year. DIS was one of the most active stocks traded on the NYSE yesterday. The Company also announced they will be expanding the Star Wars Franchise and will create two Star Wars spinoffs.

Vocus Inc. (Nasdaq: [ VOCS ]) - Vocus Inc. was one of the biggest losers in the Nasdaq yesterday, dropping 13.64% at the close. The stock closed at $15.32 but went as low as $13.48 on Wednesday. VOCS traded 1,680,508 shares yesterday, a big increase from its average of 129,069 shares. The Company had strong Q4 earnings, but issued discouraging guidance for 2013 including the year's first quarter. For the first quarter, Vocus is projecting revenue of $46.3 million to $46.7 million and non-GAAP profits of 9-10 cents a share; Street consensus had been $49 million and 13 cents.

BIOLASE, Inc. (Nasdaq: [ BIOL ]) - BIOL shares saw a big boost on Wednesday closing at $3.38, up $0.55 (19.43%). The stock hit a new 52-week high yesterday of $3.93 on trading volume over three million shares compared to an average of 98,519. The U.S. Food and Drug Administration (FDA) has cleared the Company's 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. BIOLASE, Inc. is the world's leading manufacturer and distributor of dental lasers.

To find similar research reports that are available for free follow the link below and sign up at [ http://www.TheStockFreak.com ]   

Disclosure: TheStockFreak.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

SOURCE [ www.thestockfreak.com ]